Cart
sales@molnova.com
STM3006
CAS No. 2499664-52-5
STM3006( —— )
Catalog No. M37332 CAS No. 2499664-52-5
STM3006 is an orally active, selective and and potent METTL3 inhibitor with antitumor activity for the study of acute myeloid leukemia (AML).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 202 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 629 | In Stock |
|
| 50MG | 986 | In Stock |
|
| 100MG | 1609 | In Stock |
|
| 200MG | 2167 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSTM3006
-
NoteResearch use only, not for human use.
-
Brief DescriptionSTM3006 is an orally active, selective and and potent METTL3 inhibitor with antitumor activity for the study of acute myeloid leukemia (AML).
-
DescriptionSTM3006 is a highly potent, selective and orally active METTL3 inhibitor. STM3006 can be used for the research of acute myeloid leukaemia (AML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2499664-52-5
-
Formula Weight519.44
-
Molecular FormulaC25H27BrN8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (240.64 mM; Ultrasonic )
-
SMILESBrC=1C=C2NN=CC2=C(C1)C=3N=NN(C3)CC=4N=C5C=CC(=CN5C4)CN6CCC(C)(C)CC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Maleimide
Maleimide (25-Pyrroledone) is a new nanoparticle surface functional group which favors easy conjugation with cell penetration peptides. The conjugation is enabled via click chemistry to preserve its biofunctions.
-
Proadrenomedullin (1...
Endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 251 nM). Also a noncompetitive nicotinic cholinergic antagonist. Inhibits nicotine-stimulated catecholamine secretion from PC12 cells in vitro, and from sympathetic nerve endings and adrenal chromaffin cells in vivo. Corresponds to amino acids 1 - 20 of proadrenomedullin. Antihypertensive.
-
Vilobelimab
Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction.
